Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

“…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”

Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

“…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”

Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

“…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”

Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

“…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”

Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications by Karel J. Hartlieb (1367880)

“…Herein, we discuss an alternative, water-soluble class of polyaromatic compounds, the 2,9-diazaperopyrenium dications, and report <i>in vitro</i> cell studies for a library of these dications. These investigations reveal that a number of 2,9-diazaperopyrenium dications show similar activities as doxorubicin toward a variety of cancer cell lines. …”

Split <i>ClvR</i>^<50cM configurations. by Georg Oberhofer (3401438)

S1 Data - by Nobutake Yamamichi (381131)

Subjects:

Characteristics of participants admitted to an intensive care unit by smoking status. by Karl Stattin (11836305)

Subjects:

Sensitivity analysis with follow-up beginning three years after baseline. by Karl Stattin (11836305)

Subjects:

Trend in PPI and H₂RA uses from 2010 to 2019 in Japan. by Nobutake Yamamichi (381131)

Subjects:

Risk of contracting any infection and pneumonia, being admitted to and intensive care unit and dying by smoking status. by Karl Stattin (11836305)

Subjects:

Sensitivity analysis only considering the underlying cause of death. by Karl Stattin (11836305)

Subjects:

30-Day mortality after first diagnosis of pneumonia. by Karl Stattin (11836305)

Subjects:

Participant characteristics by smoking status in 1997: Never, former or current. by Karl Stattin (11836305)

Subjects:

Sensitivity analysis adjusting for self-rated health. by Karl Stattin (11836305)

Subjects:

Sensitivity analysis adjusting for body mass index. by Karl Stattin (11836305)

Subjects:

Risk of contracting any infection and pneumonia, being admitted to and intensive care unit and dying by pack years and years since smoking cessation. by Karl Stattin (11836305)

Subjects:

Sensitivity analysis with time from baseline as time scale. by Karl Stattin (11836305)

Subjects:

Cohort flowchart. by Karl Stattin (11836305)

Subjects:

Regression output from analyses of smoking status. by Karl Stattin (11836305)

Subjects: